纽根资产管理有限公司对艾匹克公司(纳斯达克代码：EPZM)进行了28.8,000美元的新投资

NewGen Asset Management Ltd bought a new position in Epizyme, Inc. (NASDAQ:EPZM – Get Rating) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 250,000 shares of the biopharmaceutical company's stock, valued at approximately $288,000.

A number of other hedge funds have also modified their holdings of EPZM. Primecap Management Co. CA grew its stake in Epizyme by 0.4% in the fourth quarter. Primecap Management Co. CA now owns 15,366,477 shares of the biopharmaceutical company's stock valued at $38,416,000 after acquiring an additional 56,100 shares during the period. Bank of America Corp DE boosted its position in Epizyme by 6,665.3% in the fourth quarter. Bank of America Corp DE now owns 2,955,970 shares of the biopharmaceutical company's stock worth $7,390,000 after purchasing an additional 2,912,277 shares during the last quarter. Morgan Stanley boosted its position in Epizyme by 33.8% in the third quarter. Morgan Stanley now owns 2,708,473 shares of the biopharmaceutical company's stock worth $13,867,000 after purchasing an additional 684,721 shares during the last quarter. Northern Trust Corp boosted its position in Epizyme by 1.3% in the fourth quarter. Northern Trust Corp now owns 948,546 shares of the biopharmaceutical company's stock worth $2,372,000 after purchasing an additional 12,285 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Epizyme by 165.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 576,484 shares of the biopharmaceutical company's stock worth $1,441,000 after purchasing an additional 359,464 shares during the last quarter. Institutional investors and hedge funds own 76.45% of the company's stock.

Get

Epizyme

alerts:

Shares of EPZM opened at $1.48 on Tuesday. The firm has a market cap of $244.02 million, a PE ratio of -0.69 and a beta of -0.44. The stock's fifty day moving average price is $0.71 and its two-hundred day moving average price is $1.30. Epizyme, Inc. has a 1 year low of $0.41 and a 1 year high of $8.43.

Epizyme (NASDAQ:EPZM – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). Epizyme had a negative net margin of 614.08% and a negative return on equity of 2,459.33%. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $10.86 million. During the same quarter in the previous year, the firm posted ($0.69) earnings per share. On average, equities analysts forecast that Epizyme, Inc. will post -1.38 EPS for the current year.

EPZM has been the topic of several research analyst reports. Wedbush cut Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. HC Wainwright cut their price objective on Epizyme from $8.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, June 3rd. Cowen cut Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price objective on the stock. in a research report on Monday, June 27th. StockNews.com started coverage on Epizyme in a research note on Thursday, June 9th. They issued a "sell" rating on the stock. Finally, Cowen lowered Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 target price on the stock. in a research note on Monday, June 27th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Epizyme has a consensus rating of "Hold" and an average target price of $3.50.

About Epizyme (Get Rating)

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

Featured Stories

• Get a free copy of the StockNews.com research report on Epizyme (EPZM)
• Hello Group Stock is Attractive Value Speculators
• PVH Corp Stock Approaching Key Support Levels
• PetVivo Holdings Is A Growth Stock Worth a Look
• Two Pet Health Stocks To Watch And One To Avoid
• 5 Reasons to Climb Aboard Carnival Stock

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme, Inc. (NASDAQ:EPZM – Get Rating).

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.